295 related articles for article (PubMed ID: 8261408)
21. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone.
Drake FH; Hofmann GA; Mong SM; Bartus JO; Hertzberg RP; Johnson RK; Mattern MR; Mirabelli CK
Cancer Res; 1989 May; 49(10):2578-83. PubMed ID: 2540903
[TBL] [Abstract][Full Text] [Related]
22. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide.
Bugg BY; Danks MK; Beck WT; Suttle DP
Proc Natl Acad Sci U S A; 1991 Sep; 88(17):7654-8. PubMed ID: 1652758
[TBL] [Abstract][Full Text] [Related]
23. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
Rothenborg-Jensen L; Hansen HF; Wessel I; Nitiss JL; Schmidt G; Jensen PB; Sehested M; Jensen LH
Anticancer Drug Des; 2001 Dec; 16(6):305-15. PubMed ID: 12375883
[TBL] [Abstract][Full Text] [Related]
24. Characterization of a DNA topoisomerase IIalpha gene rearrangement in adriamycin-resistant P388 leukemia: expression of a fusion messenger RNA transcript encoding topoisomerase IIalpha and the retinoic acid receptor alpha locus.
McPherson JP; Brown GA; Goldenberg GJ
Cancer Res; 1993 Dec; 53(24):5885-9. PubMed ID: 8261398
[TBL] [Abstract][Full Text] [Related]
25. Development and properties of an etoposide-resistant human leukaemic CCRF-CEM cell line.
Patel S; Austin CA; Fisher LM
Anticancer Drug Des; 1990 Feb; 5(1):149-57. PubMed ID: 2156515
[TBL] [Abstract][Full Text] [Related]
26. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
[TBL] [Abstract][Full Text] [Related]
27. A novel use for the comet assay: detection of topoisomerase II inhibitors.
Salti GI; Das Gupta TK; Constantinou AI
Anticancer Res; 2000; 20(5A):3189-93. PubMed ID: 11062742
[TBL] [Abstract][Full Text] [Related]
28. Drastic reduction of topoisomerase II alpha associated with major acquired resistance to topoisomerase II active agents but minor perturbations of cell growth.
Hashimoto S; Chatterjee S; Ranjit GB; Bao C; Ford J; Ganapathi R; Berger SJ; Berger NA
Oncol Res; 1995; 7(7-8):407-16. PubMed ID: 8747604
[TBL] [Abstract][Full Text] [Related]
29. Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA.
Fernandes DJ; Danks MK; Beck WT
Biochemistry; 1990 May; 29(17):4235-41. PubMed ID: 2163274
[TBL] [Abstract][Full Text] [Related]
30. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
31. Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors.
van der Zee AG; de Jong S; Keith WN; Hollema H; Boonstra H; de Vries EG
Cancer Res; 1994 Feb; 54(3):749-55. PubMed ID: 8306337
[TBL] [Abstract][Full Text] [Related]
32. Cyclic AMP-dependent protein kinase type I is involved in hypersensitivity of human breast cells to topoisomerase II inhibitors.
Tortora G; Ciardiello F; Damiano V; Pepe S; Bianco C; di Isernia G; Davies SL; North P; Harris AL; Hickson ID
Clin Cancer Res; 1995 Jan; 1(1):49-56. PubMed ID: 9815886
[TBL] [Abstract][Full Text] [Related]
33. [Cellular resistance to DNA-topoisomerase II inhibitors].
Jacquemin-Sablon A; Bojanowski K; Casabianca-Pignède MR; Crémier S; Delaporte C; Khelifa T; Markovits J; René B; Saucier JM; Larsen AK
Bull Cancer; 1994 May; 81(5):381-5. PubMed ID: 7749214
[TBL] [Abstract][Full Text] [Related]
34. Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells.
Friche E; Danks MK; Schmidt CA; Beck WT
Cancer Res; 1991 Aug; 51(16):4213-8. PubMed ID: 1678312
[TBL] [Abstract][Full Text] [Related]
35. Association of human DNA topoisomerase IIalpha with mitotic chromosomes in mammalian cells is independent of its catalytic activity.
Mo YY; Beck WT
Exp Cell Res; 1999 Oct; 252(1):50-62. PubMed ID: 10502399
[TBL] [Abstract][Full Text] [Related]
36. Catalytic inhibitors of topoisomerase II are DNA-damaging agents: induction of chromosomal damage by merbarone and ICRF-187.
Wang L; Eastmond DA
Environ Mol Mutagen; 2002; 39(4):348-56. PubMed ID: 12112387
[TBL] [Abstract][Full Text] [Related]
37. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.
Harker WG; Slade DL; Parr RL; Feldhoff PW; Sullivan DM; Holguin MH
Cancer Res; 1995 Apr; 55(8):1707-16. PubMed ID: 7712479
[TBL] [Abstract][Full Text] [Related]
38. Induction of the differentiation of WEHI-3B D+ monomyelocytic leukemia cells by inhibitors of topoisomerase II.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1990 Oct; 50(20):6723-30. PubMed ID: 2170008
[TBL] [Abstract][Full Text] [Related]
39. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1992 May; 52(10):2782-90. PubMed ID: 1316227
[TBL] [Abstract][Full Text] [Related]
40. Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line.
Feldhoff PW; Mirski SE; Cole SP; Sullivan DM
Cancer Res; 1994 Feb; 54(3):756-62. PubMed ID: 8306338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]